Tenecteplase and return of spontaneous circulation after refractory cardiopulmonary arrest.
Even with the benefit of cardiopulmonary resuscitation, the prognosis of cardiac arrest remains poor. Multiple case series describe survival with the use of thrombolytic therapy for refractory cardiac arrest. Presumably thrombolysis treats that subset of cardiac arrest cases resulting from fulminant pulmonary embolism, or perhaps massive myocardial infarctions. Published reports to date have dealt exclusively with streptokinase, urokinase, reteplase, or recombinant tissue plasminogen activator. The authors report the first case of return of spontaneous circulation with the administration of tenecteplase. Tenecteplase is a recently developed reengineered isomer of tissue plasminogen activator that possesses many properties of the ideal cardiac arrest thrombolytic agent. It is bolus dosed, stable at room temperature before reconstitution, and is compatible with most other advanced cardiac life support medications. Because of clinical equivalency and its logistical advantages, tenecteplase should be evaluated as an alternative to other thrombolytics in future trials involving cardiac arrest.
Adams
Bruce D
BD
US Army, Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA. bruce.adams@amedd.army.mil
Kim
James Y
JY
Jackson
Walter O
WO
D000368:Aged; D001775:Blood Circulation / Q000187:drug effects; D017809:Fatal Outcome; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006323:Heart Arrest / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011183:Postoperative Complications; D011655:Pulmonary Embolism / Q000188:drug therapy; D000077785:Tenecteplase; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase